SCHEMBL765399

SCHEMBL765399

O=Cc1cncn1Cc1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 11/20 0.67
CYP11B2 P19099 11/20 0.67
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP19A1 P11511 2/20 0.42
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
IDO1 P14902 1/20 0.41
MITF O75030 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.40
NFATC1 O95644 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7983220 0.95 CYP11B1 (0.62) CYP11B1CYP11B2HTTSMN1; SMN2ALDH1A1
SCHEMBL1758083 0.85 CYP11B1 (0.68) CYP11B1CYP11B2HTTSMN1; SMN2ALDH1A1
SCHEMBL18307216 0.84 CYP11B1 (0.49) CYP11B1CYP11B2SMN1; SMN2ALDH1A1CYP19A1
SCHEMBL7696780 0.84 CYP11B1 (0.67) CYP11B1CYP11B2HTTSMN1; SMN2ALDH1A1
SCHEMBL7700254 0.84 CYP11B1 (0.67) CYP11B1CYP11B2ALDH1A1CYP19A1IDO1
SCHEMBL8140959 0.84 CYP11B1 (0.67) CYP11B1CYP11B2ALDH1A1CYP19A1IDO1
SCHEMBL7986619 0.84 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1IDO1
SCHEMBL7696643 0.83 CYP11B1 (0.66) CYP11B1CYP11B2ALDH1A1CYP19A1IDO1
SCHEMBL1757759 0.83 CYP11B1 (0.66) CYP11B1CYP11B2ALDH1A1CYP19A1IDO1
SCHEMBL8134371 0.83 CYP11B1 (0.62) CYP11B1CYP11B2SMN1; SMN2ALDH1A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2025-04-10 US disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-1422218-B1 ANTIVIRAL AGENT SHIONOGI & CO (JP) 2012-03-21 EP disclosed
EP-2181985-A1 Antiviral Agent SHIONOGI & CO., LTD. (JP) 2010-05-05 EP disclosed
US-20020156113-A1 Farnesyl transferase inhibitors; anticancer agents LES LABORATOIRES SERVIER (FR) 2002-10-24 US disclosed
WO-2002057258-A1 CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2002-07-25 WO disclosed
WO-2002057257-A1 CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR LES LABORATOIRES SERVIER (FR) 2002-07-25 WO disclosed
EP-1225170-A2 Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier S.A. (FR) 2002-07-24 EP disclosed
EP-1054882-A1 CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Aventis Pharma S.A. (FR) 2000-11-29 EP disclosed
WO-1999041248-A1 CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 1999-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS FNTA, FNTB, FDPS CYP11B1 3101/4885CYP11B2 3669/4885HTT 4327/4885
US-20020156113-A1 Farnesyl transferase inhibitors; anticancer agents COASY, FNTA, FNTB CYP11B1 147/4885CYP11B2 399/4885HTT 4285/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI CYP11B1 1632/4885CYP11B2 2129/4885HTT 4541/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI CYP11B1 1632/4885CYP11B2 2129/4885HTT 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.